arXiv:2606. 17867v1 Announce Type: cross Abstract: Despite increasing adoption of multimodal approaches in Alzheimer's Disease (AD) research -- aimed at integrating molecular, structural, clinical, and genetic biomarkers to enhance disease characterization -- the relationships among these modalities remain poorly understood.
By Antonio Scardace, Daniele Rav\`i
arXiv:2606. 17420v1 Announce Type: cross Abstract: Tau PET imaging is central to tracking Alzheimer's disease progression, but systematic differences between scanners, protocols, and radiotracers across sites introduce nonbiological variability that inflates biomarker variance, reduces sensitivity to disease effects, and can bias downstream clinical assessments.
By Jianwei Zhang, Xinyu Nie, Jiaxin Yue, Yonggang Shi
arXiv:2606. 15784v1 Announce Type: new Abstract: Alzheimer's disease (AD) progression is often described through the amyloid-tau-neurodegeneration, or AT(N), cascade.
By Nguyen Linh Dan Le
Alzheimer's disease (AD) progression is often described through the amyloid-tau-neurodegeneration, or AT(N), cascade. However, most longitudinal models represent this cascade either as a fixed sequence of biomarkers or as a black-box forecasting task.
arXiv:2602. 22545v3 Announce Type: replace-cross Abstract: Tau positron emission tomography supports Alzheimer's disease staging but is difficult to scale because of tracer, scanner, and radiation constraints.
By Agamdeep S. Chopra, Caitlin Neher, Tianyi Ren, Juampablo E. Heras Rivera, Hesamoddin Jahanian, Mehmet Kurt
arXiv:2508.17171v3 Announce Type: replace
Abstract: Imaging biomarkers in magnetic resonance imaging (MRI) are important tools for diagnosing, tracking and treating Alzheimer's disease (AD). Neurofib...
By Yue Li, Pulkit Khandelwal, Rohit Jena, Long Xie, Michael Duong, Amanda E. Denning, Christopher A. Brown, Laura E. M. Wisse, Sandhitsu R. Das, David A. Wolk, Paul A. Yushkevich